{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:07:55Z","timestamp":1777982875057,"version":"3.51.4"},"reference-count":105,"publisher":"Sociedade Brasileira de Cardiologia","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,29]]},"DOI":"10.36660\/abc.20201362","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T19:19:30Z","timestamp":1659381570000},"page":"328-341","source":"Crossref","is-referenced-by-count":3,"title":["Rastreamento, Diagn\u00f3stico e Manejo da Fibrila\u00e7\u00e3o Atrial em Pacientes com C\u00e2ncer: Evid\u00eancias Atuais e Perspectivas Futuras"],"prefix":"10.36660","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8837-2746","authenticated-orcid":false,"given":"Pedro","family":"Gon\u00e7alves-Teixeira","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9625-1124","authenticated-orcid":false,"given":"Telma","family":"Costa","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5876-2348","authenticated-orcid":false,"given":"Isabel","family":"Fragoso","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2904-8580","authenticated-orcid":false,"given":"Diogo","family":"Ferreira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9913-0435","authenticated-orcid":false,"given":"Mariana","family":"Brand\u00e3o","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-3596","authenticated-orcid":false,"given":"Adelino","family":"Leite-Moreira","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Sampaio","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2165-7680","authenticated-orcid":false,"given":"Jos\u00e9","family":"Ribeiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2306-8393","authenticated-orcid":false,"given":"Ricardo","family":"Fontes-Carvalho","sequence":"additional","affiliation":[]}],"member":"22636","reference":[{"issue":"2","key":"key20220801151429_B1","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons","volume":"140","author":"January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Jr., et al. 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125-e151. doi: 10.1161\/CIR.0000000000000665","journal-title":"Circulation"},{"issue":"5","key":"key20220801151429_B2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of C.ardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of C.ardio-Thoracic Surgery (EACTS). Eur Heart J.2021;42(5):373-498. doi: 10.1093\/eurheartj\/ehaa612.","journal-title":"Eur Heart J"},{"issue":"8","key":"key20220801151429_B3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study","volume":"27","author":"Heeringa","year":"2006","unstructured":"Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27(8):949-53. doi: 10.1093\/eurheartj\/ehi825","journal-title":"Eur Heart J"},{"issue":"4","key":"key20220801151429_B4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/jamacardio.2016.0280","article-title":"Risk of Malignant Cancer Among Women With New-Onset Atrial Fibrillation","volume":"1","author":"Conen","year":"2016","unstructured":"Conen D, Wong JA, Sandhu RK, Cook NR, Lee IM, Buring JE, et al. Risk of Malignant Cancer Among Women With New-Onset Atrial Fibrillation. JAMA Cardiol. 2016;1(4):389-96. doi: 10.1001\/jamacardio.2016.0280.","journal-title":"JAMA Cardiol"},{"key":"key20220801151429_B5","doi-asserted-by":"crossref","first-page":"8985273","DOI":"10.1155\/2019\/8985273","article-title":"Association of Cancer and the Risk of Developing Atrial Fibrillation: A Systematic Review and Meta-Analysis","volume":"2019","author":"Yuan","year":"2019","unstructured":"Yuan M, Zhang Z, Tse G, Feng X, Korantzopoulos P, Letsas KP, et al. Association of Cancer and the Risk of Developing Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cardiol Res Pract. 2019;2019:8985273. doi: 10.1155\/2019\/8985273.","journal-title":"Cardiol Res Pract"},{"issue":"5","key":"key20220801151429_B6","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11739-011-0701-9","article-title":"Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case-control study","volume":"7","author":"Erichsen","year":"2012","unstructured":"Erichsen R, Christiansen CF, Mehnert F, Weiss NS, Baron JA, S\u00f8rensen HT. Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case-control study. Intern Emerg Med. 2012;7(5):431-8. doi: 10.1007\/s11739-011-0701-9.","journal-title":"Intern Emerg Med"},{"issue":"17","key":"key20220801151429_B7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009543","article-title":"Atrial Fibrillation and Risk of Cancer: A Danish Population-Based Cohort Study","volume":"7","author":"Vinter","year":"2018","unstructured":"Vinter N, Christesen AMS, Fenger-Gr\u00f8n M, Tj\u00f8nneland A, Frost L. Atrial Fibrillation and Risk of Cancer: A Danish Population-Based Cohort Study. J Am Heart Assoc.2018;7(17):e009543. doi: 10.1161\/JAHA.118.009543.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"key20220801151429_B8","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1186\/s12885-019-6314-9","article-title":"Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12 year follow up study","volume":"19","author":"Jakobsen","year":"2019","unstructured":"Jakobsen CB, Lamberts M, Carlson N, Lock-Hansen M, Torp-Pedersen C, Gislason GH, et al. Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12 year follow up study. BMC Cancer. 2019;19(1):1105. doi: 10.1186\/s12885-019-6314-9.","journal-title":"BMC Cancer"},{"issue":"8","key":"key20220801151429_B9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102861","article-title":"Atrial fibrillation as a marker of occult cancer","volume":"9","author":"Ostenfeld","year":"2014","unstructured":"Ostenfeld EB, Erichsen R, Pedersen L, Farkas DK, Weiss NS, S\u00f8rensen HT. Atrial fibrillation as a marker of occult cancer. PloS One. 2014;9(8):e102861. doi: 10.1371\/journal.pone.0102861.","journal-title":"PloS One"},{"issue":"6","key":"key20220801151429_B10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/europace\/euq080","article-title":"The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines","volume":"12","author":"Pisters","year":"2010","unstructured":"Pisters R, van Oostenbrugge RJ, Knottnerus IL, de Vos CB, Boreas A, Lodder J, et al. The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines. Europace.2010;12(6):779-84. doi: 10.1093\/europace\/euq080.","journal-title":"Europace"},{"issue":"2","key":"key20220801151429_B11","first-page":"127","article-title":"Atrial fibrillation and cancer; understanding the mysterious relationship through a systematic review","volume":"10","author":"Lateef","year":"2020","unstructured":"Lateef N, Kapoor V, Ahsan MJ, Latif A, Ahmed U, Mirza M, et al. Atrial fibrillation and cancer; understanding the mysterious relationship through a systematic review. J Comm Community Hosp Intern Med Perspectiv. 2020;10(2):127-32. doi: 10.1080\/20009666.2020.1726571.","journal-title":"J Comm Community Hosp Intern Med Perspectiv"},{"issue":"9","key":"key20220801151429_B12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/SMJ.0b013e3182299e6c","article-title":"Atrial fibrillation in cancer patients: an underrecognized condition","volume":"104","author":"Velagapudi","year":"2011","unstructured":"Velagapudi P, Turagam MK, Kocheril AG. Atrial fibrillation in cancer patients: an underrecognized condition. Southern Med J. 2011;104(9):667-8. doi: 10.1097\/SMJ.0b013e3182299e6c.","journal-title":"Southern Med J"},{"key":"key20220801151429_B13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.gene.2017.11.015","article-title":"The unrecognized role of tumor suppressor genes in atrial fibrillation","volume":"642","author":"Mao","year":"2018","unstructured":"Mao L, Huang W, Zou P, Dang X, Zeng X. The unrecognized role of tumor suppressor genes in atrial fibrillation. Gene. 2018;642:26-31. doi: 10.1016\/j.gene.2017.11.015.","journal-title":"Gene"},{"issue":"9","key":"key20220801151429_B14","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.0000028399.42411.13","article-title":"Systemic inflammation, atrial fibrillation, and cancer","volume":"106","author":"Guzzetti","year":"2002","unstructured":"Guzzetti S, Costantino G, Fundar\u00f2 C. Systemic inflammation, atrial fibrillation, and cancer. Circulation. 2002;106(9):e40. doi: 10.1161\/01.cir.0000028399.42411.13.","journal-title":"Circulation"},{"issue":"4","key":"key20220801151429_B15","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1161\/01.CIR.96.4.1180","article-title":"Histological substrate of atrial biopsies in patients with lone atrial fibrillation","volume":"96","author":"Frustaci","year":"1997","unstructured":"Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96(4):1180-4. doi: 10.1161\/01.cir.96.4.1180.","journal-title":"Circulation"},{"issue":"1","key":"key20220801151429_B16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijcard.2003.12.028","article-title":"C-reactive protein and microalbuminuria are associated with atrial fibrillation","volume":"98","author":"Asselbergs","year":"2005","unstructured":"Asselbergs FW, van den Berg MP, Diercks GF, van Gilst WH, van Veldhuisen DJ. C-reactive protein and microalbuminuria are associated with atrial fibrillation. Int J Cardiol. 2005;98(1):73-7. doi: 10.1016\/j.ijcard.2003.12.028.","journal-title":"Int J Cardiol"},{"issue":"10","key":"key20220801151429_B17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jacc.2010.02.066","article-title":"Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population","volume":"56","author":"Marott","year":"2010","unstructured":"Marott SC, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-Hansen A, et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J Am Coll Cardiol. 2010;56(10):789-95. doi: 10.1016\/j.jacc.2010.02.066.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"key20220801151429_B18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/jir.2008.0082.2906","article-title":"Interleukin-2 as a predictor of early postoperative atrial fibrillation after cardiopulmonary bypass graft (CABG)","volume":"29","author":"Hak","year":"2009","unstructured":"Hak \u0141, My\u015bliwska J, Wieckiewicz J, Szyndler K, Siebert J, Rogowski J. Interleukin-2 as a predictor of early postoperative atrial fibrillation after cardiopulmonary bypass graft (CABG). J Interferon Cytokine Res. 2009;29(6):327-32. doi: 10.1089\/jir.2008.0082.2906.","journal-title":"J Interferon Cytokine Res"},{"issue":"2","key":"key20220801151429_B19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.hrthm.2009.10.004","article-title":"Intracardiac and extracardiac markers of inflammation during atrial fibrillation","volume":"7","author":"Marcus","year":"2010","unstructured":"Marcus GM, Smith LM, Ordovas K, Scheinman MM, Kim AM, Badhwar N, et al. Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm. 2010;7(2):149-54. doi: 10.1016\/j.hrthm.2009.10.004","journal-title":"Heart Rhythm"},{"issue":"4","key":"key20220801151429_B20","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.hrthm.2009.12.009","article-title":"Role of inflammation and oxidative stress in atrial fibrillation","volume":"7","author":"Li","year":"2010","unstructured":"Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM, et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm. 2010;7(4):438-44. doi: 10.1016\/j.hrthm.2009.12.009.","journal-title":"Heart Rhythm"},{"issue":"6917","key":"key20220801151429_B21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7. doi: 10.1038\/nature01322.","journal-title":"Nature"},{"key":"key20220801151429_B22","first-page":"98","article-title":"Chronic inflammation in cancer development","volume":"2","author":"Multhoff","year":"2011","unstructured":"Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol. 2011;2:98. doi: 10.3389\/fimmu.2011.00098","journal-title":"Front Immunol"},{"issue":"10","key":"key20220801151429_B23","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","unstructured":"Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014;63(10):945-53. doi: 10.1016\/j.jacc.2013.11.026.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"key20220801151429_B24","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.athoracsur.2010.03.100","article-title":"Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database","volume":"90","author":"Onaitis","year":"2010","unstructured":"Onaitis M, D\u2019Amico T, Zhao Y, O\u2019Brien S, Harpole D. Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. Ann Thorac Surg.2010;90(2):368-74. doi: 10.1016\/j.athoracsur.2010.03.100.","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"key20220801151429_B25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00595-013-0616-3","article-title":"Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients","volume":"44","author":"Ojima","year":"2014","unstructured":"Ojima T, Iwahashi M, Nakamori M, Nakamura M, Katsuda M, Iida T, et al. Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients. Surg Today. 2014;44(5):839-47. doi: 10.1007\/s00595-013-0616-3","journal-title":"Surg Today"},{"issue":"3","key":"key20220801151429_B26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11739-008-0124-4","article-title":"First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation","volume":"3","author":"Guzzetti","year":"2008","unstructured":"Guzzetti S, Costantino G, Vernocchi A, Sada S, Fundar\u00f2 C. First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation. emergency Intern Emerg Med. 2008;3(3):227-31. doi: 10.1007\/s11739-008-0124-4.","journal-title":"emergency Intern Emerg Med"},{"issue":"7","key":"key20220801151429_B27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0002-9343(02)01029-X","article-title":"Colorectal cancer and atrial fibrillation: a case-control study","volume":"112","author":"Guzzetti","year":"2002","unstructured":"Guzzetti S, Costantino G, Sada S, Fundar\u00f2 C. Colorectal cancer and atrial fibrillation: a case-control study. Am J Med. 2002;112(7):587-8. doi: 10.1016\/s0002-9343(02)01029-x.","journal-title":"Am J Med"},{"issue":"1","key":"key20220801151429_B28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis","volume":"128","author":"Leong","year":"2016","unstructured":"Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016;128(1):138-40. doi: 10.1182\/blood-2016-05-712828","journal-title":"Blood"},{"issue":"5","key":"key20220801151429_B29","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"Shatzel","year":"2017","unstructured":"Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017;15(5):835-47. https:\/\/doi.org\/10.1111\/jth.13651","journal-title":"J Thromb Haemost"},{"issue":"5","key":"key20220801151429_B30","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1161\/JAHA.116.004880","article-title":"Normalization of Testosterone Levels After Testosterone Replacement Therapy Is Associated With Decreased Incidence of Atrial Fibrillation","volume":"6","author":"Sharma","year":"2017","unstructured":"Sharma R, Oni OA, Gupta K, Sharma M, Sharma R, Singh V, et al. Normalization of Testosterone Levels After Testosterone Replacement Therapy Is Associated With Decreased Incidence of Atrial Fibrillation. J Am Heart Assoc. 2017;6(5):835-47. doi: 10.1016\/j.mayocpiqo.2017.05.003.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"key20220801151429_B31","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-8. doi: 10.1016\/j.jacc.2005.01.015.","journal-title":"J Am Coll Cardiol"},{"key":"key20220801151429_B32","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.2147\/CMAR.S185202","article-title":"Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges","volume":"11","author":"Martin Huertas","year":"2019","unstructured":"Martin Huertas R, Saavedra Serrano C, Perna C, Ferrer G\u00f3mez A, Alonso Gordoa T. Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges. Cancer Manag Med Res. 2019;11:4541-8. doi: 10.2147\/CMAR.S185202.","journal-title":"Cancer Manag Med Res"},{"issue":"4","key":"key20220801151429_B33","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ahj.2004.06.032","article-title":"Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study","volume":"149","author":"Flaker","year":"2005","unstructured":"Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R, et al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149(4):657-63. doi: 10.1016\/j.ahj.2004.06.032.","journal-title":"Am Heart J"},{"issue":"5","key":"key20220801151429_B34","doi-asserted-by":"crossref","first-page":"509.e2","DOI":"10.1016\/j.amjmed.2014.11.026","article-title":"Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry","volume":"128","author":"Boriani","year":"2015","unstructured":"Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH, et al. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med. 2015;128(5):509-18.e2. doi: 10.1016\/j.amjmed.2014.11.026.","journal-title":"Am J Med"},{"issue":"2","key":"key20220801151429_B35","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/STROKEAHA.116.015071","article-title":"Stroke as the Initial Manifestation of Atrial Fibrillation: The Framingham Heart Study","volume":"48","author":"Lubitz","year":"2017","unstructured":"Lubitz SA, Yin X, McManus DD, Weng LC, Aparicio HJ, Walkey AJ, et al. Stroke as the Initial Manifestation of Atrial Fibrillation: The Framingham Heart Study. Stroke. 2017;48(2):490-2. DOI: 10.1016\/j.amjmed.2014.11.026","journal-title":"Stroke"},{"key":"key20220801151429_B36","doi-asserted-by":"crossref","first-page":"i4482","DOI":"10.1136\/bmj.i4482","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"Odutayo","year":"2016","unstructured":"Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482. doi: 10.1136\/bmj.i4482.","journal-title":"BMJ"},{"issue":"19","key":"key20220801151429_B37","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1093\/eurheartj\/ehm308","article-title":"Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF)","volume":"28","author":"Friberg","year":"2007","unstructured":"Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J. 2007;28(19):2346-53. doi: 10.1093\/eurheartj\/ehm308.","journal-title":"Eur Heart J"},{"issue":"14","key":"key20220801151429_B38","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/eurheartj\/ehs469","article-title":"All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study","volume":"34","author":"Andersson","year":"2013","unstructured":"Andersson T, Magnuson A, Bryngelsson IL, Fr\u00f8bert O, Henriksson KM, Edvardsson N, et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J. 2013;34(14):1061-7. DOI: 10.1093\/eurheartj\/ehs469","journal-title":"Eur Heart J"},{"issue":"12","key":"key20220801151429_B39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209687","article-title":"Mortality and causes of death in patients with atrial fibrillation: A nationwide population-based study","volume":"13","author":"Lee","year":"2018","unstructured":"Lee E, Choi EK, Han KD, Lee H, Choe WS, Lee SR, et al. Mortality and causes of death in patients with atrial fibrillation: A nationwide population-based study. PloS One. 2018;13(12):e0209687. DOI: 10.1371\/journal.pone.0209687","journal-title":"PloS One"},{"key":"key20220801151429_B40","first-page":"519","article-title":"Atrial Fibrillation and Non-cardiovascular Diseases: A Systematic Review","volume":"105","author":"Ferreira","year":"2015","unstructured":"Ferreira C, Provid\u00eancia R, Ferreira MJ, Gon\u00e7alves LM. Atrial Fibrillation and Non-cardiovascular Diseases: A Systematic Review. Arq Bras Cardiol. 2015;105:519-26. doi: 10.5935\/abc.20150142.","journal-title":"Arq Bras Cardiol"},{"key":"key20220801151429_B41","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1749-8090-7-4","article-title":"Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study","volume":"7","author":"Imperatori","year":"2012","unstructured":"Imperatori A, Mariscalco G, Riganti G, Rotolo N, Conti V, Dominioni L. Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study. J Cardiothor Surg. 2012;7:4. doi: 10.1186\/1749-8090-7-4.","journal-title":"J Cardiothor Surg"},{"issue":"10","key":"key20220801151429_B42","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/europace\/eux177","article-title":"Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci\u00f3n Card\u00edaca y Electrofisiolog\u00eda (SOLAECE)","volume":"19","author":"Mairesse","year":"2017","unstructured":"Mairesse GH, Moran P, Van Gelder IC, Elsner C, Rosenqvist M, Mant J, et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci\u00f3n Card\u00edaca y Electrofisiolog\u00eda (SOLAECE). Europace. 2017;19(10):1589-623. doi: 10.1093\/europace\/eux177.","journal-title":"Europace"},{"issue":"6","key":"key20220801151429_B43","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1160\/TH14-03-0231","article-title":"Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study","volume":"111","author":"Lowres","year":"2014","unstructured":"Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost. 2014;111(6):1167-76. doi: 10.1160\/TH14-03-0231","journal-title":"Thromb Haemost"},{"issue":"25","key":"key20220801151429_B44","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1161\/CIRCULATIONAHA.114.014343","article-title":"Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study","volume":"131","author":"Svennberg","year":"2015","unstructured":"Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. Circulation. 2015;131(25):2176-84. doi: 10.1161\/CIRCULATIONAHA.114.014343.","journal-title":"Circulation"},{"issue":"7","key":"key20220801151429_B45","article-title":"Diagnostic Performance of a Smartphone-Based Photoplethysmographic Application for Atrial Fibrillation Screening in a Primary Care Setting","volume":"5","author":"Chan","year":"2016","unstructured":"Chan PH, Wong CK, Poh YC, Pun L, Leung WW, Wong YF, et al. Diagnostic Performance of a Smartphone-Based Photoplethysmographic Application for Atrial Fibrillation Screening in a Primary Care Setting. J Am Heart J.2016;5(7):e003428.","journal-title":"J Am Heart J"},{"issue":"20","key":"key20220801151429_B46","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1901183","article-title":"Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation","volume":"381","author":"Perez","year":"2019","unstructured":"Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. N Engl J Med. 2019;381(20):1909-17. doi: 10.1056\/NEJMoa1901183.","journal-title":"N Engl J Med"},{"issue":"7616","key":"key20220801151429_B47","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1136\/bmj.39280.660567.55","article-title":"Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial","volume":"335","author":"Fitzmaurice","year":"2007","unstructured":"Fitzmaurice DA, Hobbs FD, Jowett S, Mant J, Murray ET, Holder R, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ.2007;335(7616):383. doi: 10.1136\/bmj.39280.660567.55.","journal-title":"BMJ"},{"issue":"19","key":"key20220801151429_B48","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1161\/CIRCULATIONAHA.117.030583","article-title":"Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study","volume":"136","author":"Halcox","year":"2017","unstructured":"Halcox JPJ, Wareham K, Cardew A, Gilmore M, Barry JP, Phillips C, et al. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study. Circulation. 2017;136(19):1784-94. doi: 10.1161\/CIRCULATIONAHA.117.030583.","journal-title":"Circulation"},{"issue":"2","key":"key20220801151429_B49","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2018.8102","article-title":"Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial","volume":"320","author":"Steinhubl","year":"2018","unstructured":"Steinhubl SR, Waalen J, Edwards AM, Ariniello LM, Mehta RR, Ebner GS, et al. Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial. JAMA. 2018;320(2):146-55. doi: 10.1001\/jama.2018.8102.","journal-title":"JAMA"},{"issue":"26","key":"key20220801151429_B50","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1056\/NEJMoa1313600","article-title":"Cryptogenic stroke and underlying atrial fibrillation","volume":"370","author":"Sanna","year":"2014","unstructured":"Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl Med.2014;370(26):2478-86. doi: 10.1056\/NEJMoa1313600.","journal-title":"N Engl Med"},{"issue":"26","key":"key20220801151429_B51","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1056\/NEJMoa1311376","article-title":"Atrial fibrillation in patients with cryptogenic stroke","volume":"370","author":"Gladstone","unstructured":"Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 014;370(26):2467-77. doi: 10.1056\/NEJMoa1311376.","journal-title":"N Engl J Med"},{"key":"key20220801151429_B52","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0735-1097(16)30882-8","article-title":"CHADS-VASC SCORE and the risk of new onset atrial fibrillation among middle age adults","volume":"67","author":"Berkovitch","year":"2016","unstructured":"Berkovitch A, Sabbag A, Segev S, Kivity S, Sidi Y, Goldenberg I, et al. CHADS-VASC SCORE and the risk of new onset atrial fibrillation among middle age adults. J Am Coll Cardiol. 2016;67(13 Suppl.):881.","journal-title":"J Am Coll Cardiol"},{"key":"key20220801151429_B53","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2147\/CIA.S206976","article-title":"CHA2DS2-VASc score can guide the screening of atrial fibrillation - cross-sectional study in a geriatric ward","volume":"14","author":"Wojszel","year":"2019","unstructured":"Wojszel ZB, Kasiukiewicz A, Swietek M, Swietek ML, Magnuszewski L. CHA2DS2-VASc score can guide the screening of atrial fibrillation - cross-sectional study in a geriatric ward. Clin Interv Aging.2019;14:879-87. doi: 10.2147\/CIA.S206976.","journal-title":"Clin Interv Aging"},{"issue":"2","key":"key20220801151429_B54","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/europace\/euw319","article-title":"Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design","volume":"19","author":"Engdahl","year":"2016","unstructured":"Engdahl J, Svennberg E, Friberg L, Al-Khalili F, Frykman V, Kemp Gudmundsdottir K, et al. Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design. Europace. 2016;19(2):297-302. doi: 10.2147\/CIA.S206976.","journal-title":"Europace"},{"issue":"2","key":"key20220801151429_B55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212974","article-title":"Assessment of N-terminal pro-B-type natriuretic peptide level in screening for atrial fibrillation in primary health care","volume":"14","author":"Ghazal","year":"2019","unstructured":"Ghazal F, Theobald H, Rosenqvist M, Al-Khalili F. Assessment of N-terminal pro-B-type natriuretic peptide level in screening for atrial fibrillation in primary health care. PloS One. 2019;14(2):e0212974. doi: 10.2147\/CIA.S206976.","journal-title":"PloS One"},{"issue":"1","key":"key20220801151429_B56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/europace\/euz255","article-title":"Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study","volume":"22","author":"Kemp Gudmundsdottir","year":"2020","unstructured":"Kemp Gudmundsdottir K, Fredriksson T, Svennberg E, Al-Khalili F, Friberg L, Frykman V, et al. Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study. Europace. 2020;22(1):24-32.","journal-title":"Europace"},{"issue":"23","key":"key20220801151429_B57","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source","volume":"378","author":"Hart","year":"2018","unstructured":"Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. NN Engl J Med. 2018;378(23):2191-201. doi: 10.1056\/NEJMoa1802686.","journal-title":"NN Engl J Med"},{"issue":"20","key":"key20220801151429_B58","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","article-title":"Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source","volume":"380","author":"Diener","year":"2019","unstructured":"Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med.2019;380(20):1906-17. doi: 10.1056\/NEJMoa1813959","journal-title":"N Engl J Med"},{"issue":"6","key":"key20220801151429_B59","article-title":"Diagnostic performance of an automatic blood pressure measurement device, Microlife WatchBP Home A, for atrial fibrillation screening in a real-world primary care setting","volume":"7","author":"Chan","year":"2017","unstructured":"Chan PH, Wong CK, Pun L, Wong YF, Wong MM, Chu DW, et al. Diagnostic performance of an automatic blood pressure measurement device, Microlife WatchBP Home A, for atrial fibrillation screening in a real-world primary care setting. BMJ. 2017;7(6):e013685. doi: 10.1136\/bmjopen-2016-013685.","journal-title":"BMJ"},{"issue":"19","key":"key20220801151429_B60","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1161\/CIRCULATIONAHA.116.026693","article-title":"Screening for atrial fibrillation with ECG to reduce stroke. A report of the AF-SCREEN International Collaborators","volume":"135","author":"Freedman","year":"2017","unstructured":"Freedman B, Camm J, Calkins H, Heally JS, Rosenqvist M, Wang J, et al. Screening for atrial fibrillation with ECG to reduce stroke. A report of the AF-SCREEN International Collaborators. Circulation.2017;135(19):1851-67. doi: 10.1161\/CIRCULATIONAHA.116.026693.","journal-title":"Circulation"},{"key":"key20220801151429_B61","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s13063-015-1082-6","article-title":"The Danish Cardiovascular Screening Trial (DANCAVAS): study protocol for a randomized controlled trial","volume":"16","author":"Diederichsen","year":"2015","unstructured":"Diederichsen AC, Rasmussen LM, S\u00f8gaard R, Lambrechtsen J, Steffensen FH, Frost L, et al. The Danish Cardiovascular Screening Trial (DANCAVAS): study protocol for a randomized controlled trial. Trials. 2015;16:554. doi: 10.1186\/s13063-015-1082-6. doi: 10.1186\/s13063-015-1082-6.","journal-title":"Trials"},{"key":"key20220801151429_B62","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ahj.2017.02.017","article-title":"Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): Rationale and design of a large randomized controlled trial","volume":"187","author":"Diederichsen","year":"2017","unstructured":"Diederichsen SZ, Haugan KJ, K\u00f8ber L, H\u00f8jberg S, Brandes A, Kronborg C, et al. Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): Rationale and design of a large randomized controlled trial. Am Heart J. 2017;187 Am Heart J.2017;187:122-32. doi: 10.1016\/j.ahj.2017.02.017.","journal-title":"Am Heart J"},{"issue":"16","key":"key20220801151429_B63","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021566","volume":"10","author":"Benjamin","year":"2021","unstructured":"Benjamin EJ, Al-Khatib SM, Desvigne-Nickens P, Alonso A, Djouss\u00e9 P, et al. J Am Heart Assoc.2021;10(16):e021566. doi: 10.1161\/JAHA.121.021566","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"key20220801151429_B64","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"Subclinical Atrial Fibrillation and the Risk of Stroke","volume":"366","author":"Healey","year":"2012","unstructured":"Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al. Subclinical Atrial Fibrillation and the Risk of Stroke. N Engl J Med. 2012;366(2):120-9. doi: 10.1056\/NEJMoa1105575.","journal-title":"N Engl J Med"},{"issue":"5","key":"key20220801151429_B65","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jama.2018.10321","article-title":"Screening for Atrial Fibrillation With Electrocardiography: US Preventive Services Task Force Recommendation Statement","volume":"320","author":"Curry","year":"2018","unstructured":"Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for Atrial Fibrillation With Electrocardiography: US Preventive Services Task Force Recommendation Statement. JAMA.2018;320(5):478-84. doi: 10.1001\/jama.2018.10321.","journal-title":"JAMA"},{"key":"key20220801151429_B66","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ahj.2016.02.011","article-title":"Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: The mHealth Screening To Prevent Strokes (mSToPS) trial","volume":"175","author":"Steinhubl","year":"2016","unstructured":"Steinhubl SR, Mehta RR, Ebner GS, Ballesteros MM, Waalen J, Steinberg G, et al. Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: The mHealth Screening To Prevent Strokes (mSToPS) trial. Am Heart J. 2016;175:77-85. doi: 10.1016\/j.ahj.2016.02.011.","journal-title":"Am Heart J"},{"issue":"4","key":"key20220801151429_B67","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.ahj.2014.06.018","article-title":"Finding atrial fibrillation in stroke patients: Randomized evaluation of enhanced and prolonged Holter monitoring--Find-AF(RANDOMISED)-rationale and design","volume":"168","author":"Weber-Kr\u00fcger","year":"2014","unstructured":"Weber-Kr\u00fcger M, Gelbrich G, Stahrenberg R, Liman J, Kermer P, Hamann GF, et al. Finding atrial fibrillation in stroke patients: Randomized evaluation of enhanced and prolonged Holter monitoring--Find-AF(RANDOMISED)-rationale and design. Am Heart J. 2014;168(4):438-45.e1. doi: 10.1016\/j.ahj.2014.06.018.","journal-title":"Am Heart J"},{"issue":"23","key":"key20220801151429_B68","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2013.08.1623","article-title":"The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation","volume":"62","author":"Rold\u00e1n","year":"2013","unstructured":"Rold\u00e1n V, Mar\u00edn F, Manzano-Fern\u00e1ndez S, Gallego P, V\u00edlchez JA, Vald\u00e9s M, et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol.2013;62(23):2199-204. doi: 10.1016\/j.jacc.2013.08.1623.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"key20220801151429_B69","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","volume":"361","author":"Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009;361(12):1139-51. doi: 10.1056\/NEJMoa0905561.","journal-title":"N Engl J Med"},{"issue":"10","key":"key20220801151429_B70","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation","volume":"365","author":"Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011;365(10):883-91. doi: 10.1056\/NEJMoa1009638.","journal-title":"N Engl J Med"},{"issue":"11","key":"key20220801151429_B71","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus Warfarin in Patients with Atrial Fibrillation","volume":"365","author":"Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011;365(11):981-92. doi: 10.1056\/NEJMoa1107039.","journal-title":"N Engl J Med"},{"issue":"22","key":"key20220801151429_B72","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus Warfarin in Patients with Atrial Fibrillation","volume":"369","author":"Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013;369(22):2093-104. doi: 10.1056\/NEJMoa1310907.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20220801151429_B73","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","unstructured":"Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632-4. doi: 10.1111\/j.1538-7836.2007.02374.x.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"key20220801151429_B74","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/2047487318759858","article-title":"CHA(2)DS(2)-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer","volume":"25","author":"D\u2019Souza","year":"2018","unstructured":"D\u2019Souza M, Carlson N, Fosb\u00f8l E, Lamberts M, Smedegaard L, Nielsen D, et al. CHA(2)DS(2)-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. Eur J Prev Cardiol. 2018;25(6):651-8. doi: 10.1177\/2047487318759858.","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"key20220801151429_B75","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.amjcard.2017.08.038","article-title":"Usefulness of CHADS2 and CHA2DS2-VASc Scores for Stroke Prediction in Patients With Cancer and Atrial Fibrillation","volume":"120","author":"Patell","year":"2017","unstructured":"Patell R, Gutierrez A, Rybicki L, Khorana AA. Usefulness of CHADS2 and CHA2DS2-VASc Scores for Stroke Prediction in Patients With Cancer and Atrial Fibrillation. Am J Cardiol. 2017;120(12):2182-6. doi: 10.1016\/j.amjcard.2017.08.038","journal-title":"Am J Cardiol"},{"issue":"2","key":"key20220801151429_B76","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijcard.2012.08.036","article-title":"Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients","volume":"165","author":"Hu","year":"2013","unstructured":"Hu YF, Liu CJ, Chang PM, Tsao HM, Lin YJ, Chang SL, et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol. 2013;165(2):355-7. doi: 10.1016\/j.ijcard.2012.08.036.","journal-title":"Int J Cardiol"},{"key":"key20220801151429_B77","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0049-3848(14)50009-6","article-title":"Bleeding complications during anticoagulant treatment in patients with cancer","volume":"133","author":"Kamphuisen","year":"2014","unstructured":"Kamphuisen PW, Beyer-Westendorf J. Bleeding complications during anticoagulant treatment in patients with cancer. Thromb Res. 2014;133 (Suppl 2):S49-55. doi: 10.1016\/S0049-3848(14)50009-6.","journal-title":"Thromb Res"},{"issue":"3","key":"key20220801151429_B78","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/ehjqcco\/qcx004","article-title":"Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry","volume":"3","author":"Melloni","year":"2017","unstructured":"Melloni C, Shrader P, Carver J, Piccini JP, Thomas L, Fonarow GC, et al. Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes. 2017;3(3):192-7. doi: 10.1093\/ehjqcco\/qcx004.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"8","key":"key20220801151429_B79","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer","volume":"380","author":"Khorana","year":"2019","unstructured":"Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019;380(8):720-8. doi: 10.1056\/NEJMoa1814630.","journal-title":"N Engl J Med"},{"issue":"8","key":"key20220801151429_B80","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer","volume":"380","author":"Carrier","year":"2018","unstructured":"Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2018;380(8):711-9. doi: 10.1056\/NEJMoa1814468.","journal-title":"N Engl J Med"},{"issue":"7","key":"key20220801151429_B81","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"Raskob","year":"2017","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med.2017; 378(7):615-24. doi: 10.1056\/NEJMoa1711948.","journal-title":"N Engl J Med"},{"issue":"20","key":"key20220801151429_B82","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)","volume":"36","author":"Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018;36(20):2017-23. doi: 10.1200\/JCO.2018.78.8034.","journal-title":"J Clin Oncol"},{"issue":"17","key":"key20220801151429_B83","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer","volume":"382","author":"Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, Mu\u00f1oz A, Huisman MV, Connors JM, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020;382(17):1599-607. doi: 10.1056\/NEJMoa1915103.","journal-title":"N Engl J Med"},{"issue":"3","key":"key20220801151429_B84","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation","volume":"2","author":"Shah","year":"2018","unstructured":"Shah S, Norby FL, Datta YH, Lutsey PL, MacLehose RF, Chen LY, et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv.2018;2(3):200-9. doi: 10.1182\/bloodadvances.2017010694.","journal-title":"Blood Adv"},{"issue":"12","key":"key20220801151429_B85","doi-asserted-by":"crossref","first-page":"1440.e1","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial","volume":"130","author":"Melloni","year":"2017","unstructured":"Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, et al. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. Am J Med. 2017;130(12):1440-8.e1. doi: 10.1016\/j.amjmed.2017.06.026.","journal-title":"Am J Med"},{"issue":"16","key":"key20220801151429_B86","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008987","article-title":"Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial","volume":"7","author":"Fanola","year":"2018","unstructured":"Fanola CL, Ruff CT, Murphy SA, Jin J, Duggal A, Babilonia NA, et al. Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial. J Am Heart Assoc. 2018;7(16):e008987. doi: 10.1161\/JAHA.118.008987.","journal-title":"J Am Heart Assoc"},{"issue":"14","key":"key20220801151429_B87","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012540","article-title":"Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis","volume":"8","author":"Deng","year":"2019","unstructured":"Deng Y, Tong Y, Deng Y, Zou L, Li S, Chen H. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2019;8(14):e012540. doi: 10.1161\/JAHA.119.012540.","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"key20220801151429_B88","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jacc.2015.04.025","article-title":"Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis","volume":"65","author":"Holmes","year":"2015","unstructured":"Holmes DR Jr., Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H, et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol. 2015;65(24):2614-23. doi: 10.1016\/j.jacc.2015.04.025.","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"key20220801151429_B89","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","article-title":"Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)","volume":"61","author":"Reddy","year":"2013","unstructured":"Reddy VY, M\u00f6bius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol. 2013;61(25):2551-6. doi: 10.1016\/j.jacc.2013.03.035.","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"key20220801151429_B90","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation","volume":"347","author":"Wyse","year":"2002","unstructured":"Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation. N Engl J Med. 2002;347(23):1825-33. doi: 10.1056\/NEJMoa021328.","journal-title":"N Engl J Med"},{"issue":"14","key":"key20220801151429_B91","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early Rhythm-Control Therapy in Patients with Atrial Fibrillation","volume":"383","author":"Kirchhof","year":"2020","unstructured":"Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med.2020; 383(14):1305-16. doi: 10.1056\/NEJMoa2019422.","journal-title":"N Engl J Med"},{"issue":"15","key":"key20220801151429_B92","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa1001337","article-title":"Lenient versus Strict Rate Control in Patients with Atrial Fibrillation","volume":"362","author":"Van Gelder","year":"2010","unstructured":"Van Gelder IC, Groenveld HF, Crijns HJGM, Tuininga YS, Tijssen JGP, Alings AM, et al. Lenient versus Strict Rate Control in Patients with Atrial Fibrillation. N Engl J Med. 2010;362(15):1363-73. doi: 10.1056\/NEJMoa1001337.","journal-title":"N Engl J Med"},{"issue":"16","key":"key20220801151429_B93","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-93. doi: 10.1093\/eurheartj\/ehy136.","journal-title":"Eur Heart J"},{"issue":"9","key":"key20220801151429_B94","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.recesp.2019.03.017","article-title":"Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendatio","volume":"72","author":"L\u00f3pez-Fern\u00e1ndez","year":"2019","unstructured":"L\u00f3pez-Fern\u00e1ndez T, Mart\u00edn-Garc\u00eda A, Rold\u00e1n Rabad\u00e1n I, Mitroi C, Maz\u00f3n Ramos P, D\u00edez-Villanueva P, et al. Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendatio. Rev Esp Cardiol. 2019;72(9):749-59. doi: 10.1016\/j.rec.2019.03.019.","journal-title":"Rev Esp Cardiol"},{"issue":"15","key":"key20220801151429_B95","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","unstructured":"Siontis KC, Zhang X, Eckard A, Bhave N, Schaubel DE, He K, et al. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation. 2018;138(15):1519-29. doi: 10.1161\/CIRCULATIONAHA.118.035418. doi: 10.1002\/rth2.12111.","journal-title":"Circulation"},{"issue":"4","key":"key20220801151429_B96","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/rth2.12111","article-title":"Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review","volume":"2","author":"Samuelson Bannow","year":"2018","unstructured":"Samuelson Bannow BR, Lee AYY, Khorana AA, Zwicker JI, Noble S, Ay C, et al. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. Res Pract Thromb Haemost.2018;2(4):644-69.. 2018;2(4):664-9. doi: 10.1002\/rth2.12111.","journal-title":"Res Pract Thromb Haemost"},{"issue":"16","key":"key20220801151429_B97","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1161\/CIR.0000000000000748","article-title":"Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association","volume":"141","author":"Chung","year":"2020","unstructured":"Chung MK, Eckhardt LL, Chen LY, Ahmed HM, Gopinathannair R, Joglar JA, et al. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. Circulation. 2020;141(16):e750-e72. doi: 10.1161\/CIR.0000000000000748.","journal-title":"Circulation"},{"issue":"21","key":"key20220801151429_B98","doi-asserted-by":"crossref","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","article-title":"Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association","volume":"139","author":"Gilchrist","year":"2019","unstructured":"Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al. Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. Circulation. 2019;139(21):e997-e1012. doi: 10.1161\/CIR.0000000000000679.","journal-title":"Circulation"},{"issue":"1","key":"key20220801151429_B99","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/epirev\/mxx007","article-title":"The Impact of Exercise on Cancer Mortality, Recurrence, and Treatment-Related Adverse Effects","volume":"39","author":"Cormie","year":"2017","unstructured":"Cormie P, Zopf EM, Zhang X, Schmitz KH. The Impact of Exercise on Cancer Mortality, Recurrence, and Treatment-Related Adverse Effects. Epidemiol Rev.2017;39(1):71-92. doi: 10.1093\/epirev\/mxx007.","journal-title":"Epidemiol Rev"},{"issue":"10201","key":"key20220801151429_B100","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0140-6736(19)31721-0","article-title":"An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction","volume":"394","author":"Attia","year":"2019","unstructured":"Attia ZI, Noseworthy PA, Lopez-Jimenez F, Asirvatham SJ, Deshmukh AJ, Gersh BJ, et al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet. (London, England). 2019;394(10201):861-7. doi: 10.1016\/S0140-6736(19)31721-0","journal-title":"Lancet"},{"issue":"10","key":"key20220801151429_B101","doi-asserted-by":"crossref","first-page":"1268.e3","DOI":"10.1016\/j.echo.2019.06.002","article-title":"Left Atrial Mechanical Dispersion Assessed by Strain Echocardiography as an Independent Predictor of New-Onset Atrial Fibrillation: A Case-Control Study","volume":"32","author":"Kawakami","year":"2019","unstructured":"Kawakami H, Ramkumar S, Nolan M, Wright L, Yang H, Negishi K, et al. Left Atrial Mechanical Dispersion Assessed by Strain Echocardiography as an Independent Predictor of New-Onset Atrial Fibrillation: A Case-Control Study. J Am Soc Echocardiogr. 2019;32(10):1268-76.e3. DOI: 10.1016\/j.echo.2019.06.002","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"key20220801151429_B102","doi-asserted-by":"crossref","first-page":"10039","DOI":"10.1038\/s41598-020-66671-w","article-title":"Early-onset atrial fibrillation patients show reduced left ventricular ejection fraction and increased atrial fibrosis","volume":"10","author":"Andreasen","year":"2020","unstructured":"Andreasen L, Bertelsen L, Ghouse J, Lundegaard PR, Ahlberg G, Refsgaard L, et al. Early-onset atrial fibrillation patients show reduced left ventricular ejection fraction and increased atrial fibrosis. Sci Rep. 2020;10(1):10039. doi: 10.1038\/s41598-020-66671-w.","journal-title":"Sci Rep"},{"issue":"2","key":"key20220801151429_B103","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.114.002769","article-title":"Association of left atrial function and left atrial enhancement in patients with atrial fibrillation: cardiac magnetic resonance study","volume":"8","author":"Habibi","year":"2015","unstructured":"Habibi M, Lima JA, Khurram IM, Zimmerman SL, Zipunnikov V, Fukumoto K, et al. Association of left atrial function and left atrial enhancement in patients with atrial fibrillation: cardiac magnetic resonance study. Circ Cardiovasc Imaging. 2015;8(2):e002769. doi: 10.1038\/s41598-020-66671-w.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"6","key":"key20220801151429_B104","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/ng.3843","article-title":"Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation","volume":"49","author":"Christophersen","year":"2017","unstructured":"Christophersen IE, Rienstra M, Roselli C, Yin X, Geelhoed B, Barnard J, et al. Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. Nat Genet. 2017;49(6):946-52. doi: 10.1038\/ng.3843.","journal-title":"Nat Genet"},{"issue":"11","key":"key20220801151429_B105","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945-60. doi: 10.1002\/ejhf.1920","journal-title":"Eur J Heart Fail"}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/abccardiol.org\/article\/rastreamento-diagnostico-e-manejo-da-fibrilacao-atrial-em-pacientes-com-cancer-evidencias-atuais-e-perspectivas-futuras\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T13:10:14Z","timestamp":1747401014000},"score":1,"resource":{"primary":{"URL":"https:\/\/abccardiol.org\/article\/rastreamento-diagnostico-e-manejo-da-fibrilacao-atrial-em-pacientes-com-cancer-evidencias-atuais-e-perspectivas-futuras\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":105,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,7,29]]}},"alternative-id":["10.36660\/abc.20201362"],"URL":"https:\/\/doi.org\/10.36660\/abc.20201362","relation":{},"ISSN":["0066-782X","1678-4170"],"issn-type":[{"value":"0066-782X","type":"print"},{"value":"1678-4170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}